| Name | Title | Contact Details |
|---|
Addiction Recovery Resources (ARR) is a Metairie, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Canadian Dermatology Association is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dio Medical is a Park Ridge, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stanford Health Care, with multiple facilities throughout the Bay Area, is internationally renowned for leading edge and coordinated care in cancer care, neurosciences, cardiovascular medicine, surgery, organ transplant, medicine specialties, and primary care. Throughout its history, Stanford has been at the forefront of discovery and innovation, as researchers and clinicians work together to improve health, alleviate suffering, and translate medical breakthroughs into better ways to deliver patient care. Stanford Health Care: Healing humanity through science and compassion, one patient at a time. At Stanford Health Care, your career is supported within a distinctive hospital culture. This environment compliments the pioneering, collaborative atmosphere that has earned us our worldwide reputation for excellence.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.